Jinan Zhuocheng Bio-Tech Co., Ltd.

Recently, the U.S. District Court in Boston issued a landmark ruling with significant implications for the pharmaceutical industry: Japanese pharma giant Takeda Pharmaceutical lost its first-instance judgment in a “Pay-for-Delay” antitrust lawsuit, with a federal jury ordering an initial damages award of $885 million. Under the U.S. antitrust law’s treble damages provision, the total penalty could ultimately rise to approximately $2.5 billion (about RMB 17 billion).

“Pay-for-Delay” agreements represent a long-debated and controversial practice in the pharmaceutical industry. The core mechanism involves brand-name drug companies facing patent challenges from generic manufacturers paying compensation or sharing market benefits in exchange for delayed generic entry, thereby extending the original drug’s market exclusivity.

This case centers on Takeda’s constipation treatment drug Amitiza (lubiprostone). Originally developed by Sucampo Pharmaceuticals, Amitiza was jointly commercialized by Takeda after its launch in 2006 and quickly became a blockbuster product, reaching peak annual sales of around $400 million during 2014–2015.

In 2012, generic manufacturer Par Pharmaceutical filed a patent challenge against Amitiza, leading to litigation between the parties. In 2014, Takeda, Sucampo, and Par reached a settlement agreement: Par agreed not to launch its own generic version until January 2021. In exchange, Par was allowed to sell an authorized generic supplied by Sucampo and share profits under a revenue-sharing arrangement.

In 2021, the settlement triggered a large-scale class-action lawsuit. Plaintiffs included drug wholesalers, healthcare funds, insurance companies, and major retailers such as CVS and Walgreens. They alleged that the agreement constituted a “reverse payment” scheme that artificially delayed lower-cost generic entry, suppressed market competition, and forced the U.S. healthcare system to overpay by hundreds of millions of dollars for Amitiza.

After a five-week trial, the Boston federal jury ruled in favor of the plaintiffs, finding Takeda liable. The $885 million compensatory damages were allocated as follows: $474.9 million to wholesaler classes, $346.8 million to retail plaintiffs, and $63.2 million to end-payor groups.

What truly shocked the industry is the mandatory treble damages rule under the U.S. Sherman Antitrust Act. Under this provision, the damages awarded to wholesalers and retailers will automatically be tripled after judgment becomes final, bringing the combined amount alone to approximately $2.465 billion. Damages for end-payors remain subject to further court proceedings. This means Takeda’s total financial exposure could approach $2.5 billion.

Following the first-instance loss, Takeda responded firmly, stating it will pursue post-trial motions and file an appeal. The company said it “strongly believes the plaintiffs’ claims lack factual and legal basis” and argued that multiple evidentiary and legal errors occurred during the trial.

From a financial perspective, Takeda is currently evaluating the provision that needs to be recorded in its FY2025 financial statements (ending March 31, 2026) and plans to revise and refile its financial disclosures accordingly. The company emphasized that the case is not expected to materially impact FY2025 core earnings or significantly alter FY2026 guidance, although adjusted free cash flow may be revised depending on the final judgment amount and payment timing.

Notably, this is not Takeda’s only recent legal challenge. Just days earlier, the company reached a settlement with the U.S. Department of Justice over a “kickback scheme” related to its antidepressant Trintellix, paying a $13.67 million penalty. Combined with a planned workforce reduction of 4,500 employees announced on May 13 and mounting patent cliffs across key products, Takeda is navigating a particularly difficult period.

Regardless of the outcome of the appeal, this case has become a watershed moment for global pharmaceutical antitrust enforcement. It marks the first time a U.S. federal jury has held a pharmaceutical company liable in a private antitrust class action involving a “Pay-for-Delay” agreement, signaling that scrutiny of reverse-payment settlements has now moved beyond regulatory enforcement into the realm of substantial civil liability.